Ignite Creation Date:
2024-05-06 @ 7:37 PM
Last Modification Date:
2024-10-26 @ 3:10 PM
Study NCT ID:
NCT06072118
Status:
COMPLETED
Last Update Posted:
2023-10-10
First Post:
2023-10-02
Brief Title:
Adrenomedullin for CADASIL
Sponsor:
National Cerebral and Cardiovascular Center Japan
Organization:
National Cerebral and Cardiovascular Center Japan
Study Overview
Official Title:
A Multicenter Single-arm Clinical Trial of Adrenomedullin for Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMCAD
Brief Summary:
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy CADASIL is the most common form of hereditary cerebral small vessel disease with no proven disease-modifying treatments Adrenomedullin a vasoactive peptide has angiogenic vasodilation anti-inflammatory and anti-oxidative properties and could have triple sites of action on components of the neuro-glial-vascular unit consisting of vessels microglia and oligodendrocytes or more specifically on the white matter oligovascular unit The aim of the AMCAD trial is to assess the safety and efficacy of Adrenomedullin in CADASIL patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| jRCT2051210117 | REGISTRY | Japan Registry of Clinical Trials | None |